Biodexa announces positive phase 2 clinical trial results of erapa™ at 12 months in familial adenomatous polyposis (fap)

June 24, 2024 biodexa pharmaceuticals plc biodexa announces positive phase 2 clinical trial results of erapa™ at 12 months in familial adenomatous polyposis (fap) overall 75% non-progression rate at 12 months median decrease in overall polyp burden at 12 months of 17% cohort 2 non-progression rate at 12 months of 81% and median decrease in poly burden of 29% informs phase 3 dosage regimen data reported in oral presentation at 2024 bi-annual insight meeting (dateline) june 24 -- biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced that 12 month results of a phase 2 clinical trial of erapa™ in familial adenomatous polyposis (“fap”) (nct04230499) were reported in an oral presentation at the prestigious 2024 insight bi-annual meeting in barcelona by carol burke, m.d., a specialist gastroenterologist at the cleveland clinic and a leading authority in fap, a mostly genetic disease of precancerous polyps for which the only current remedy is surgical removal of the colon and/or rectum.
BDRX Ratings Summary
BDRX Quant Ranking